PL2380587T3 - Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu - Google Patents

Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Info

Publication number
PL2380587T3
PL2380587T3 PL11172880T PL11172880T PL2380587T3 PL 2380587 T3 PL2380587 T3 PL 2380587T3 PL 11172880 T PL11172880 T PL 11172880T PL 11172880 T PL11172880 T PL 11172880T PL 2380587 T3 PL2380587 T3 PL 2380587T3
Authority
PL
Poland
Prior art keywords
inhibitor
ischemia
reperfusion injury
prevention
reperfusion
Prior art date
Application number
PL11172880T
Other languages
English (en)
Inventor
Maurice Mannesse
Johannes Henricus Nuijens
Frank Pieper
Simoni Maria Grazia De
Gijsbertus Johannes Ziere
Original Assignee
Pharming Intellectual Property B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharming Intellectual Property B.V. filed Critical Pharming Intellectual Property B.V.
Publication of PL2380587T3 publication Critical patent/PL2380587T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL11172880T 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu PL2380587T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05112630 2005-12-21
US76094406P 2006-01-23 2006-01-23
EP06824316A EP1965831B1 (en) 2005-12-21 2006-12-19 Use of c1 inhibitor for the prevention of ischemia-reperfusion injury
EP11172880.4A EP2380587B1 (en) 2005-12-21 2006-12-19 Use of C1 inhibitor for the prevention of ischemia-reperfusion injury

Publications (1)

Publication Number Publication Date
PL2380587T3 true PL2380587T3 (pl) 2018-03-30

Family

ID=38016640

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06824316T PL1965831T3 (pl) 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego
PL11172880T PL2380587T3 (pl) 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do zapobiegania uszkodzeniu niedokrwiennoreperfuzyjnemu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL06824316T PL1965831T3 (pl) 2005-12-21 2006-12-19 Zastosowanie inhibitora C1 do profilaktyki uszkodzenia niedokrwienno-reperfuzyjnego

Country Status (15)

Country Link
US (3) US8071532B2 (pl)
EP (2) EP2380587B1 (pl)
JP (2) JP5394748B2 (pl)
KR (1) KR101508668B1 (pl)
AT (1) ATE516043T1 (pl)
AU (1) AU2006327989B2 (pl)
CA (1) CA2632400C (pl)
CY (2) CY1112452T1 (pl)
DK (1) DK2380587T3 (pl)
HR (2) HRP20110622T1 (pl)
IL (2) IL192180A (pl)
NZ (1) NZ568749A (pl)
PL (2) PL1965831T3 (pl)
SI (1) SI2380587T1 (pl)
WO (1) WO2007073186A2 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035802A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
PL3028716T3 (pl) * 2006-10-10 2021-03-08 Regenesance B.V. Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
JP5423266B2 (ja) * 2009-09-14 2014-02-19 富士電機株式会社 デジタル制御スイッチング電源装置
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CA2829037C (en) 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
WO2013041677A1 (en) 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
WO2013082458A1 (en) 2011-12-02 2013-06-06 The Regents Of The University Of California Reperfusion protection solution and uses thereof
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
WO2014008242A1 (en) * 2012-07-03 2014-01-09 The Trustees Of Columbia University In The City Of New York The use of interleukin-11 to protect against ischemia and reperfusion injury
CN110818798A (zh) 2012-10-25 2020-02-21 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
GB2509260B (en) 2012-11-02 2016-05-04 True North Therapeutics Inc Anti-complement C1s antibodies and uses thereof
WO2014131865A1 (en) * 2013-02-28 2014-09-04 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
AU2014224599B2 (en) * 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
KR20150135242A (ko) 2013-03-15 2015-12-02 샤이어 바이로파마 인코포레이티드 C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법
PL3013366T3 (pl) * 2013-06-28 2022-01-17 Csl Behring Gmbh Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
ES2788697T3 (es) * 2014-11-03 2020-10-22 Thrombolytic Science Llc Métodos y composiciones para trombólisis segura y eficaz
SI3280440T1 (sl) 2015-04-06 2023-03-31 Bioverativ Usa Inc. Humanizirana protitelesa proti C1S in načini uporabe
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
WO2017087882A1 (en) * 2015-11-19 2017-05-26 Shire Human Genetic Therapies, Inc. Recombinant human c1 esterase inhibitor and uses thereof
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
EP3504648A1 (en) 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
FI3525583T3 (fi) 2016-10-12 2025-10-31 Bioverativ Usa Inc Anti-c1s-vasta-aineita ja niiden käyttömenetelmiä
US11154596B2 (en) 2017-06-16 2021-10-26 Thrombolytic Science, Llc Methods for thrombolysis
EP3681517B1 (en) 2017-09-15 2024-05-08 Cedars-Sinai Medical Center C1 esterase inhibitors for use in improving organ function in organ transplant patients
JP2021515757A (ja) 2018-02-28 2021-06-24 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． 子癇前症の治療及び予防
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210078527A (ko) 2018-10-17 2021-06-28 체에스엘 베링 게엠베하 C1-inh의 정제 방법
WO2021001525A1 (en) 2019-07-04 2021-01-07 Csl Behring Gmbh Process for purifying c1-inh
KR102191500B1 (ko) 2020-03-30 2020-12-15 국립낙동강생물자원관 초석잠 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
KR102217607B1 (ko) 2020-06-01 2021-02-18 국립낙동강생물자원관 석창포 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
KR102191452B1 (ko) 2020-06-30 2020-12-15 주식회사 에이치비헬스케어 곶감 추출물을 포함하는 기억력 및 인지기능 개선, 허혈 재관류 손상 예방 및 개선용 조성물
CA3198740A1 (en) 2020-11-20 2022-05-27 John Roberts Method for treating antibody-mediated rejection
US20240342258A1 (en) 2021-07-09 2024-10-17 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE264111T1 (de) 1999-05-14 2004-04-15 Steffen Thiel Neue indikationen für mannan-binding lectin (mbl) zur behandlung von immungeschwächten patienten
WO2001057079A2 (en) * 2000-01-31 2001-08-09 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
JP2004100982A (ja) * 2002-09-05 2004-04-02 Denso Corp 熱交換器
WO2004035802A1 (en) * 2002-10-17 2004-04-29 Pharming Intellectual Property B.V. Protein modification
NZ543646A (en) * 2003-05-16 2009-09-25 Pharming Intellectual Pty Bv C1 inhibitor with short half-life for transient treatment
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden

Also Published As

Publication number Publication date
HRP20110622T1 (hr) 2011-09-30
US20130244941A1 (en) 2013-09-19
EP2380587B1 (en) 2017-10-25
IL192180A0 (en) 2009-02-11
DK2380587T3 (en) 2017-12-04
IL228954A0 (en) 2013-12-31
IL228954A (en) 2016-10-31
KR101508668B1 (ko) 2015-04-06
EP2380587A1 (en) 2011-10-26
PL1965831T3 (pl) 2011-12-30
AU2006327989B2 (en) 2012-06-07
NZ568749A (en) 2011-05-27
SI2380587T1 (en) 2018-03-30
ATE516043T1 (de) 2011-07-15
WO2007073186A2 (en) 2007-06-28
JP5394748B2 (ja) 2014-01-22
HRP20171738T1 (hr) 2018-01-26
EP1965831A2 (en) 2008-09-10
KR20080098001A (ko) 2008-11-06
CA2632400A1 (en) 2007-06-28
AU2006327989A1 (en) 2007-06-28
CA2632400C (en) 2016-06-07
US20120088728A1 (en) 2012-04-12
US9211318B2 (en) 2015-12-15
IL192180A (en) 2013-10-31
WO2007073186A3 (en) 2007-08-09
CY1112452T1 (el) 2015-12-09
JP2013126992A (ja) 2013-06-27
US8071532B2 (en) 2011-12-06
US8415288B2 (en) 2013-04-09
JP2009520815A (ja) 2009-05-28
US20080305993A1 (en) 2008-12-11
EP1965831B1 (en) 2011-07-13
CY1119818T1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
IL228954A0 (en) Use of C1 inhibitors for the prevention of ischemia-reperfusion injuries
MX2007007409A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos.
MX2009008338A (es) Compuestos de piridopirimidinona de utilidad en el tratamiento de enfermedades o condiciones patologicas mediadas por los canales de sodio.
UA101943C2 (ru) Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
IL191629A0 (en) Tricyclic amide derivatives useful for treating obesity
IL189694A0 (en) Biphenyl derivatives and their use in treating hepatitis c
GB0225475D0 (en) Therapeutic agents
UA92355C2 (en) urn:schemas-microsoft-com:office:smarttags2,4-DIAMINO-PYRIMIDINES USED AS AURORAINHIBITORS
WO2003002530A3 (en) Pyrrolidines as dipeptidyl peptidase inhibitors
ZA200704910B (en) Pyrrolidine inhibitors of IAP
WO2008151288A3 (en) Aromatic and heteroaromatic compounds useful in treating iron disorders
IL193252A0 (en) N-hydroxyacrylamide compounds
MX2009010083A (es) Compuestos biarilo y biheteroarilo de utilidad en el tratamiento de trastornos de hierro.
UA87843C2 (ru) Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий
PL1855677T3 (pl) 3,11B-Cis-dihydrotetrabenazyny do leczenia schizofrenii i innych psychoz
WO2006079547A3 (en) Spm 927 for add-on therapy of schizophrenia
PL1919466T3 (pl) Formulacje do leczenia nieprawidłowości lipoproteinowych obejmujące statynę i pochodną metylonikotynoamidu
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
MY145823A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
EP2036555A4 (en) USE OF PYRIDONE DERIVATIVES FOR THE PREVENTION AND TREATMENT OF RADIOACTIVE LUNG INJURY
WO2009148600A8 (en) Deuterated lysine-based compounds
TW200738643A (en) Cyclourea compounds and the use thereof
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
TW200637538A (en) Lacosamide for add-on-therapy
EP1251847A4 (en) NEW USE OF PRODIGIOSINE TO TREAT DIABETES